BCI
The evaluation of human epidermal growth factor receptor 2 (HER2) expression is essential to formulate a precise treatment for breast cancer. The routine evaluation of HER2 is conducted with immunohistochemical techniques (IHC), which is very expensive. Therefore, we propose a breast cancer immunohistochemical (BCI) benchmark attempting to synthesize IHC data directly with the paired hematoxylin and eosin (HE) stained images. The dataset contains 4870 registered image pairs, covering a variety of HER2 expression levels (0, 1+, 2+, 3+).